Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Spherix Global Insights

< Previous 1 2 3 4 Next >
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
From Spherix Global Insights
Via GlobeNewswire
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
From Spherix Global Insights
Via GlobeNewswire
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
From Spherix Global Insights
Via GlobeNewswire
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
From Spherix Global Insights
Via GlobeNewswire
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
From Spherix Global Insights
Via GlobeNewswire
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
From Spherix Global Insights
Via GlobeNewswire
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
From Spherix Global Insights
Via GlobeNewswire
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
From Spherix Global Insights
Via GlobeNewswire
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
From Spherix Global Insights
Via GlobeNewswire
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
From Spherix Global Insights
Via GlobeNewswire
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
From Spherix Global Insights
Via GlobeNewswire
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
From Spherix Global Insights
Via GlobeNewswire
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
From Spherix Global Insights
Via GlobeNewswire
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
From Spherix Global Insights
Via GlobeNewswire
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
From Spherix Global Insights
Via GlobeNewswire
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
From Spherix Global Insights
Via GlobeNewswire
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Spherix Introduces Patient Chart Dynamix™, an Enhanced Independent Pharmaceutical Market Research Chart Audit
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Announces New Leadership to Drive Growth and Innovation
From Spherix Global Insights
Via GlobeNewswire
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
From Spherix Global Insights
Via GlobeNewswire
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
From Spherix Global Insights
Via GlobeNewswire
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
From Spherix Global Insights
Via GlobeNewswire
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
From Spherix Global Insights
Via GlobeNewswire
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.